Neurology

Discussion in 'Valeant Pharmaceuticals' started by anonymous, Sep 22, 2017 at 7:24 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Allegedly 2020 but they may pull the plug sooner if they don't add to the portfolio.
     

  2. anonymous

    anonymous Guest

    What's up with reps being moved to different districts? It's bad enough that the pay is extraordinarily low for this specialty position and then 2 of the 3 managers are terrible with their reps. Sad times.
     
  3. anonymous

    anonymous Guest

    To the above thread:
    Reps get moved around all the time to different districts. Really not a big deal. Means nothing.
     
  4. anonymous

    anonymous Guest

    It's a big deal to any reps moved to the North or West. Those managers have driven off almost half the salesforce.
     
  5. anonymous

    anonymous Guest

    stop being a wimp. All managers are fine
     
  6. anonymous

    anonymous Guest

    You know nothing troll. Go find a life.
     
  7. anonymous

    anonymous Guest

    You must have meant the North and the West. Another rep from the North just left last week. The low salary isn't worth the aggravation of Bausch management and the constantly changing RX numbers.
     
  8. anonymous

    anonymous Guest

    It sure seemed like quite a few McKinley folks got shafted at the Sarasota POA. I guess if you don't kiss the ring or hang out with the upper management at the bars you aren't in the exclusive Golden Guy/Golden Girl club. What a joke.
     
  9. anonymous

    anonymous Guest

    The joke is the high amount of suspicious scripts coming out of TX. The manager in the North doesn't appear to be in the cool clique either, which seemed pretty evident in Sarasota. This place is shady.
     
  10. anonymous

    anonymous Guest

    The cronyism was on full display at that sales meeting. The final 2018 numbers are suspect too. No wonder people are leaving left and right.
     
  11. anonymous

    anonymous Guest

    More reps will leave as the CGRPs continue to cut into the rescue med share. There are also a couple CGRP acute treatments coming out so Migranal will continue to lose share. The window for opportunity is just about gone no matter what management says. You better have a Plan B.
     
  12. anonymous

    anonymous Guest

    Just like all that koolaid must taste real good to you Bausch Bot.
     
  13. anonymous

    anonymous Guest

    Does anybody find it strange that Bausch decided to dramatically drop the objective for Migranal this quarter? On the one hand it seems like they were trying to make it easy to blow plan away in order to get new products from J. Papa this year. It just seems odd they'd take money off the table for them to earn. I wonder if they jacked the WAC up?
     
  14. anonymous

    anonymous Guest

    It's an absolute crime of epic unethical proportions as to how much Bausch is charging for Migranal!!! $3900??? Are you serious???!!! It's a 20 year old product and many providers are not interested, regardless of the copay cards.

    We're all paying for that overpriced drug in our insurance premiums. Shame on you Bausch!!! You're just as bad as Pharma Bro, Martin Shkreli, and the Bausch executives who endorsed this pricing belong in jail with Martin!
     
  15. anonymous

    anonymous Guest

    The entire management team is incompetent which is why the salesforce is a revolving door.
     
  16. anonymous

    anonymous Guest

    So the person Bausch specifically brought into Bausch Neurology to grow the portfolio and salesforce is leaving for another position in the organization after less than 2 years. Has the portfolio grown? Have they grown the salesforce? No. Get your resumes ready.
     
  17. anonymous

    anonymous Guest

    Not looking good. I hear certain managers are threatening improvements plans if folks don't bring up their numbers to finish 1st quarter strong. So ridiculous. It's no wonder a bunch of folks left for better jobs when you have managers threatening you over a declining 20 year old product competing against multiple new products. Pathetic.
     
  18. anonymous

    anonymous Guest

    That is happening company wide!! This company was much better when MP was the CEO!!
     
  19. anonymous

    anonymous Guest

    Iqvia is hiring a whole salesforce for an adhd drug. The benefits are better there than with Alamo and the management has to be better than Bausch.
     
  20. anonymous

    anonymous Guest

    You mean Yolande?